Results 221 to 230 of about 1,078,822 (357)

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

The effectiveness of monetary policy [PDF]

open access: yes
The analysis addresses changing views of the role and effectiveness of monetary policy, inflation targeting as an "effective monetary policy," monetary policy and short-run (output) stabilization, and problems in implementing a short-run stabilization ...
Marcela M. Williams, Robert H. Rasche
core  

Parental choice of private tuition: Valuing attention, judging quality and navigating access in England's underregulated supplementary education market

open access: yesBritish Educational Research Journal, EarlyView.
Abstract Private supplementary education is burgeoning worldwide, and over 25% of English children have received private tutoring. The neoliberalisation of education and parents' responsibilisation for children's attainment have driven market growth, but not all can afford to participate.
Sarah L. Holloway   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy